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Abstract
We previously reported that the common toxic gain-of-function in various mutant copper-zinc superoxide dismutases
(SOD1) seen in patients with familial amyotrophic lateral sclerosis (ALS) was an abnormal copper release from the
enzyme protein. In this study, trientine and ascorbate, known to have a bene®cial effect in an animal model of Wilson
disease, were administered to transgenic mice overexpressing a mutated human SOD1 (G93A). The onset of neurolo-
gical signs in the treated group was signi®cantly delayed compared with that in the control group, and the time to reach
total paralysis in the treated group was delayed as well. Since the agents used in this study cause low toxicity in animals
and humans, this treatment may be a good candidate for clinical application. q 1999 Elsevier Science Ireland Ltd. All
rights reserved.
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Amyotrophic lateral sclerosis (ALS) is a fatal progressive
motor neuron disease with unknown etiology. About 10% of
patients are familial (FALS), and the copper-zinc superox-
ide dismutase (SOD 1) gene is mutated in approximately
20% of FALS cases [6,17]. Transgenic mice overexpressing
a mutated human SOD1 develop neurological signs and
pathological changes similar to FALS cases [10], although
mice that overexpress a wild-type human SOD1 or mice
with disrupted SOD1 gene have no change in motor neurons
[10,16]. This indicates that the adversely acquired toxicity
in mutant SOD1 contributes to the degeneration of motor
neurons. In this regard, we previously reported that the
release of copper ions from mutant SOD1 was a possible
toxic gain-of-function [15].
Triethylenetetramine dihydrochloride (trientine), a
chelating agent for copper, and ascorbate are known to
have a bene®cial effect in Long Evans Cinnamon (LEC)
rats, an animal model for Wilson disease, in reducing copper
toxicity [11,18]. Since we hypothesized that the copper toxi-
city in motor neurons would contribute to the pathogenesis
of FALS, we examined the neuroprotective effect of a
combined treatment with trientine and ascorbate in FALS
transgenic mice. Part of the present study has been reported
in abstract form [14].
Transgenic mice overexpressing a human SOD1 gene
carrying Glycine 93 ! Alanine mutation were obtained
from The Jackson Laboratory (Bar Harbor, ME) (the strain
designation B6SJL-TgN(SOD1-G93A)1Gurdl) and main-
tained as hemizygotes in the B6SJL background. The
onset of neurological signs in this strain is delayed
compared to the original strain [10] because of a reduction
in transgenic copy number according to the information
from The Jackson Laboratory. Transgenic progeny was
identi®ed by a polymerase chain reaction (PCR) on genomic
DNA using ex4Pla 5 0-CATCAGCCCTAATCCATCTGA-
3 0 and ex4P2a 5 0-TGGATCTTAGAATTCGCGAC-3 0, a
pair of speci®c primers for the exon 4 of the human SOD1
gene. PCR was conducted with 32 cycles at 948C for 1 min,
608C for 1 min and 728C for 1 min. Non-transgenic
offsprings were used as controls. All animals were handled
in accordance with the Guideline for the Care and Use of
Laboratory Animals at the Osaka University Graduate
School of Medicine.
Trientine was kindly provided by Tsumura&Co. Eight
mice were fed with L(1)-ascorbate (Wako Pure Chemical,
Osaka, Japan) mixed in the standard diet AIN-93G (Oriental
Yeast, Tokyo, Japan) at the concentration of 0.8% w/w and
trientine in distilled water at the concentration of 0. 2% w/v
ad libitum beginning at 45 days of age. Seven mice fed with
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the diet AIN-93G and distilled water alone were used as the
control group. The treatment was continued until mice
reached the end-point. The diet was supplemented twice a
week and distilled water was changed once a week.
The clinical signs and body weights of mice were moni-
tored twice a week after entry into the protocol. We deter-
mined the onset of the neurological signs by subtle postural
change of one limb and the end-point by the total paralysis
of hindlimbs, when a mouse was lifted by the tail. The data
were expressed as mean ^ SD per group. Survival analysis
was performed by Kaplan±Meier method and the statistical
difference was determined by Mantel±Cox test using soft-
ware StatView-5.0 for Macintosh (SAS Institute, Cary, NC).
P , 0:05 was considered to be signi®cant.
Fig. 1 indicates cumulative probabilities of the disease
onset (Fig. 1A) and end-point (Fig. 1B) for mice in each
group. Since two mice in the treated group died accidentally
after the onset but before the end-point, they were censored
in the analysis of the end-point. The untreated mice showed
initial signs at a mean age of 195:4 ^ 11:3 days, whereas the
treated mice showed them at a mean age of 211:8 ^ 12:2
days (Table 1). The combined treatment signi®cantly
delayed the disease onset (Fig. 1A, Mantel±Cox test,
P  0:030). The untreated and treated mice reached the
end-point at a mean age of 244:3 ^ 20:5 and 269:7 ^ 19:3
days, respectively (Table 1). The end-point was also signif-
icantly delayed by the treatment (Fig. 1B, P  0:045).
The mean body weight of the treated mice increased more
than that of the untreated mice, and the body weight of the
treated mice still kept increasing even after that of the
untreated mice reached the peak (Fig. 2).
There was no difference in the amount of water intake
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Fig. 1. Cumulative probability of the disease onset (A) and survival (B) in control or treated FALS mice. The onset of the disease and end-
point were signi®cantly delayed in the treated group.
Table 1
Effects of the treatment with trientine and ascorbate on the
disease onset and end-point in FALS micea
Control group Treated group P-value
Onset (days) 195.4 ^ 11.3 211.8 ^ 12.2 0.030
End-point (days) 244.3 ^ 20.5 269.7 ^ 19.3 0.045
a The data were expressed as mean ^ SD. The statistical differ-
ence was determined by Mantel±Cox test.
Fig. 2. Change in the body weight of control and treated FALS
mice. The body weight of the treated mice increased more than
that of the control mice, and still increased even after the body
weight of the control mice reached the peak.
between the two groups (2.5 ml/day). The expected dose of
trientine taken by the treated group was 125±l70 mg/kg
weight/day. There was no clinical untoward effect of the
agents among the treated animals.
We have demonstrated that the treatment with trientine
and ascorbate has a protective effect on the onset of the
disease and the end-point in FALS transgenic mice. The
body weight in the treated mice peaked later, possibly by
the treatment, because the decline of body weight has been
correlated with the disease advance [4]. Thus, chelating of
copper ions and protection from oxidative stress appear to
be bene®cial in this FALS model. We previously found that
mutant SOD1 from erythrocytes of FALS patients possessed
abnormal copper peaks in ion exchange chromatographic
fractions without relation to SOD1 activities [15], suggest-
ing that free copper ions released from rapidly-degraded or
loosely-folded mutants might be involved in the pathogen-
esis of FALS. Corson et al. [5] also suggested that the SOD1
mutant-mediated disease was caused by aberrant copper-
mediated chemistry catalyzed by less tightly folded mutant
enzymes. Taken together, the copper-mediated oxidative
stress seems to be very attractive as the common nature of
toxic gain-of-function in FALS with SOD1 mutation.
Although copper ions are essential for activation of many
cuproproteins such as SOD1, the excessive concentration of
copper ions is toxic to cells. Free cupric ion (Cu21) can be
reduced by superoxide to cuprous ion (Cu1), which then
reacts with hydrogen peroxide to generate hydroxyl radical
(Fenton or Haber±Weiss reaction). Hydroxyl radical
oxidizes intracellular components including lipid
membranes, proteins and nucleic acids, and cause cellular
damage [1].
Wilson disease is an autosomal recessive disease with a
defect in the cellular export system of copper ions, and
manifests with cellular damage in the liver and the central
nervous system [3]. In LEC rats that possess the gene defect
homologous to that in Wilson disease [20], free radicals
produced by accumulated copper in the liver are thought
to cause oxidative injury to hepatocytes [1], where copper
chelating agents including trientine and antioxidants includ-
ing ascorbate have been reported to delay the onset of hepa-
titis [11,18]. Trientine is also known to decrease the
formation of hydroxyl radicals from cuprous ions in vitro
[8]. Ascorbate works as an antioxidant by scavenging free
radicals, although it can also have a pro-oxidant property in
the presence of copper ions by reducing them for Fenton
reaction [2]. In general, ascorbate at a high concentration or
in the presence of low level of copper ions acts as an anti-
oxidant rather than a pro-oxidant [2]. Since we used ascor-
bate in combination with trientine at the same concentration
as used in the study of LEC rats [11], we believe that ascor-
bate functioned as an antioxidant.
The present study suggested that the elimination of the
oxidative stress mediated by copper ions from mutant SOD1
would suppress the degeneration of motor neurons in FALS.
Gurney et al. [9] showed the ef®cacy of vitamin E in delay-
ing the clinical onset but not extending the survival period in
FALS mice. They suggested that peroxidation of lipid
membranes inhibited by vitamin E was related to delay in
the disease initiation, but other factors such as glutamate
excitotoxicity were related to the disease progression.
Thus, a lack of bene®cial effect of vitamin E on survival
might be explained by the fact that it inhibited lipid perox-
idation but not oxidation of other intracellular components
[13]. After we had initiated the present study, Hottinger et
al. [12] reported that d-penicillamine, another copper chelat-
ing agent, had a signi®cant bene®t on the disease onset and
survival of FALS mice when it was administered orally by
force. Taken together, removal of copper ions may become
a novel therapeutical approach to FALS patients. D-penicil-
lamine at a high dose can cause many adverse effects. Trien-
tine is regarded as an alternative agent for penicillamine-
intolerant patients with Wilson disease because of its less
frequent adverse effects [19]. It has been reported that
normal B6C3F1 mice administered trientine at 3000 ppm
in water for 90 days showed no adverse clinical sign [7].
Thus, this treatment may be a good candidate for clinical
application. It is now necessary to determine whether the
administration of trientine alone or ascorbate alone before
onset or after onset has a bene®cial effect on FALS mice,
and whether a combined therapy with other agents effective
on FALS mice such as riluzole [9] can extend the survival
period.
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